Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VXCO-102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Dose 1 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8 |
| Group 2 | EXPERIMENTAL | Dose 2 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8 |
| Group 3 | EXPERIMENTAL | Dose 3 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8 |
| Group 4 | PLACEBO_COMPARATOR | Sodium Chloride administered IM by needle and syringe at Day 1 and Week 8 |
| Name | Type | Description |
|---|---|---|
| VXCO-102 | BIOLOGICAL | Sterile liquid for injection |
| Placebo | BIOLOGICAL | 0.9% sodium chloride (BP grade) |
Inclusion Criteria: * Aged 18 to 25 years, inclusive * Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment Exclusion Criteria: * Self-reported or medically-documented significant medical or psychiatric condition that ...
VXCO-102 is an investigational monoclonal antibody being developed by Eli Lilly and Company for Epstein-Barr virus, or EBV. It is in Phase 1 clinical development. Because it is still being studied in clinical trials, VXCO-102 is not an approved therapy and is not yet available for general use.
VXCO-102 is being studied for Epstein-Barr virus, or EBV. The single registered Phase 1 trial is described as an mRNA vaccine targeting EBV in healthy young adults, conducted in Australia. The trial is not yet recruiting and is designed to enroll 45 participants aged 18 years and older.
VXCO-102 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Eli Lilly is the sponsor of the Phase 1 trial evaluating VXCO-102 in Epstein-Barr virus, and no other developer or partner is identified for this asset.
VXCO-102 is in Phase 1 clinical development. One Phase 1 trial has been registered for the asset, and it is currently active but not yet recruiting. No Phase 2 or later studies have been registered, and the program has not reported any completed trials to date.
VXCO-102 is being evaluated in one registered Phase 1 trial, NCT07557602, titled mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults. The trial is not yet recruiting, is placebo controlled and double blinded, and plans to enroll 45 participants in Australia.
VXCO-102 is not approved. It is an investigational monoclonal antibody in Phase 1 clinical development for Epstein-Barr virus, and its only registered trial, NCT07557602, has not yet begun recruiting. Approval status would only change if the program advances through later-stage trials and regulatory review.